Ketamine infusions vs Spravato
Both target the glutamate system for treatment-resistant depression, but they differ in molecule, route, FDA status, insurance coverage, and clinical evidence base. This guide compares them across the decisions patients actually face.
This page has been written and edited by the publisher. It has not been reviewed by a licensed clinician.
This page compares Ketamine infusions (IV/IM) and Spravato (esketamine nasal spray) across the same fixed dimensions - mechanism, evidence, onset, duration, side effects, access, suitability, and limits. It does not name a winner and does not recommend either option for you.
Publisher and editor of Ketalux, based in Chicago, Illinois. Ira is a ketamine therapy patient, not a clinician. This is editorial review, not medical review: Ira is not a licensed clinician and does not provide diagnosis or medical care. Ketalux does not accept compensation from providers in exchange for favorable editorial coverage, evidence ratings, recommendations, patient referrals, or organic provider ranking. Read the full publisher disclosure →
Educational use only. The content on this page is provided for general educational purposes and does not constitute medical advice, diagnosis, or treatment. Ketamine and related therapies carry risks and are appropriate only under qualified medical supervision. Always consult a licensed healthcare professional about your individual situation. Information may change as research evolves.
